TheEdgeResearch
Home / Stocks / SLNX

Solanbridge Group, Inc. (SLNX)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$476,000
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
-6.84
52-Wk Range
0.000001-0.0001
CEO
David J. Cutler
Country
US
Currency
USD

Solanbridge Group, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Lakewood, CO, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $476,000. On trailing twelve-month figures it carries a trailing P/E of -7.14, a net margin of 0.0%. Its beta of -6.84 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-7.14
Price / Sales
0.00
Price / Book
-5.31
EV / EBITDA
-7.03
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.16
Current ratio
0.04
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
0
IPO date
2007-06-29
Headquarters
Lakewood, CO, US
About Solanbridge Group, Inc.

Solanbridge Group, Inc. concentrates its efforts on cultivating and marketing medical cannabis in Nova Scotia, Canada. Additionally, the organization is committed to developing and distributing a range of CBD-enriched products throughout Nevada, California, and Colorado. The enterprise was founded in 2000 and maintains its main corporate offices in The Woodlands, Texas.

Comparable companies

Solanbridge Group, Inc. is most often compared with the following Healthcare names:

DKSCERBBFITXFTEGGEATFGRCUGRPSSTEKVRTHFXBRAF
More research on SLNX
SLNX technical analysis SLNX TheEdge Score Compare against peers
Open full interactive analysis & DCF →